- Live, attenuated oral vaccine indicated for immunization to prevent rotavirus gastroenteritis in infants and children:
- Monovalent: PO 1mL *1 at 6 weeks and at 10 weeks, prior to 24 weeks of age for 2 total doses
- Start before 15 weeks old
- Monovalent: PO 1mL *1 at 6 weeks and at 10 weeks, prior to 24 weeks of age for 2 total doses
-
- Pentavalent: PO 2mL *1 at 6 weeks, 10 weeks and 14weeks prior to 24 weeks of age for 3 total doses
- Third dose should not be given after 32 weeks of age
- Pentavalent: PO 2mL *1 at 6 weeks, 10 weeks and 14weeks prior to 24 weeks of age for 3 total doses
Injection:
- Monovalent
- Pentavalent
None remarkable
Oral vaccine
It induces antibody formation
- Diarrhea
- Vomiting
- Otitis media
- Nasopharyngitis
- Irritability
- Hypersensitivity
- Immunosuppression
- Infants with severe combined immunodeficiency disease (SCID)
- Infants aged <6 weeks and >32 weeks
- History of uncorrected congenital malformation of the GI tract that would predispose infant to intussusception
- Infants with a history of intussusception
- Belimumab
- Certolizumab pegol
- Ibrutinib
- Ifosfamide
- Ixekizumab
- Lomustine
- Mechlorethamine
- Melphalan
- Methotrexate
- Onasemnogene abeparvovec
- Oxaliplatin
- Procarbazine
- Secukinumab
- Ustekinumab
Drug Status
| Availability | Prescription only |
| Pregnancy | Not indicated |
| Breastfeeding | Not indicated |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Rotarix | FDC | Suspension | 1D | GSK Ltd | GSK Ltd |
| Rotasil Thermo | FDC | Suspension | 1D | Serum Institute | Sai Pharma |
| Rotateq | FDC | Suspension | 1D | MSD Ltd | Imperial Managed |
| Rotavac | FDC | Suspension | 1D | Bharat Biotech | Nairobi Enterprises |